During the project period, 12 laboratory syntheses were developed for the active ingredients, and for 5 active ingredients, scale-up to pilot plant size was also achieved. For professional or economic reasons, we terminated 3 developments after the laboratory phase and another 3 after the pilot plant scale-up. The active ingredients developed in the project were incorporated into 4 preparations during the formulation development, and further incorporation of active ingredients is expected in the future.

One preparation has already been introduced to the market and is generating revenue for Egis. The development of certain preparations was halted due to polymorphism and stability issues, while our other developments are progressing without interruptions according to the planned schedule. Due to patent reasons, the introduction of additional products from the portfolio is expected after 2030. Timely developments allow for the possibility of these generic drugs being marketed in countries where Egis does not have a commercial organization, through partnerships. During the project, numerous professional achievements were made, enhancing our oncological drug development capabilities and practical knowledge. Beyond the revenue generated by the products realized with the support, the project indirectly contributes to the development of further drugs and the future sustainable success of the company's oncological portfolio.